News & Events

Immuno-Oncology 360° 2022 Summit

IO360˚convenes stakeholders from the science and business communities to report on the latest data impacting IO to fight a wider range of cancers.

Read more
Festival of Biologics USA 2022

Speaker: Li Hui M.D., Ph.D., Director, Antibody Discovery & RenMice Licensing, Biocytogen Boston Corp Time: 5:10pm PST, March 9th Talk title: Streamlining Therapeutic Antibody Discovery…

Read more
Webinar: Mouse Models to Investigate New Treatments for Inflammatory Disease

We’re pleased to continue our new webinar series informing and updating our network of research professionals. We invite you to join us to learn about…

Read more
Biocytogen/Eucure Biopharma Announce the Completion of First Patient Dosing for Phase II Clinical Trial of YH003 in Australia

Beijing, China, December 9, 2021/PRNewswire/ – Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase II clinical trial…

Read more
2021 Highlights: Humanized Model Publications

We are proud to highlight our growing list of publications featuring off-the-shelf and customized mouse, rat, and cancer cell models in well-respected, high-impact journals. Featured below…

Read more
Biocytogen/Eucure Biopharma Announce the Completion of First Patient Dosing for Phase I Clinical Trial of YH004 (Anti-4-1BB Monoclonal Antibody) in Australia

BEIJING, CHINA, December 7, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I clinical trial of…

Read more
Biocytogen/Eucure Biopharma’s YH001 (Anti-CTLA-4 Monoclonal Antibody) Approved for Phase II Multi-Regional Clinical Trial by China National Medical Products Administration

BEIJING, November 9, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing proprietary antibody drugs, announced that the China National Medical Products Administration…

Read more
Webinar: Investigating Inflammatory Disease using Humanized Cytokine Mice

Our webinar “Investigating Inflammatory Disease using Humanized Cytokine Mice” was live on Dec 1, 2021 at 1PM. In this webinar, we will: - Review the…

Read more
Biocytogen/Eucure Biopharma’s YH003 (Anti-CD40 Monoclonal Antibody) Approved for Phase II Multi-Regional Clinical Trial by China National Medical Products Administration

BEIJING, November 2, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing proprietary antibody drugs, announced that the China National Medical Products Administration…

Read more
Eucure Biopharma, a Subsidiary of Biocytogen, and TRACON Pharmaceuticals Announce Partnership for Development of Clinical Stage CTLA-4 Antibody YH001

YH001 is a potential best-in-class CTLA-4 antibody with enhanced ADCC and CDC effector functions   YH001 is currently being dosed in multiple Phase 1 oncology trials…

Read more
Back to top